BEFORE THE BELL-Acadia Pharma soars on deal with Biovail unit

NEW YORK, May 4 (Reuters) - Shares of Acadia Pharmaceuticals Inc (ACAD.O) more than doubled to $2.33 in premarket trade on Monday, after the company said it entered into a deal with a unit of Biovail Corp (BVF.N) to co-develop and commercialize its experimental drug designed to treat Parkinson's disease psychosis.

For details, see [ID:nBNG489486] (Reporting by Ryan Vlastelica; Editing by Theodore d'Afflisio)